Cargando…
Long-term survival of a BRCA2 mutation carrier following second ovarian cancer relapse using PARPi therapy: A case report
BRCA1/2 mutation carriers have lifelong increased risks of developing breast and ovarian cancer. Due to the lack of efficient ovarian cancer screening, patients mainly present when the tumors are at an advanced stage, and the long-term survival is poor. The application of poly(ADP-ribose) polymerase...
Autores principales: | Bredow, Kathrin, Blümcke, Britta, Schneider, Stephanie, Püsken, Michael, Schmutzler, Rita, Rhiem, Kerstin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353872/ https://www.ncbi.nlm.nih.gov/pubmed/35949895 http://dx.doi.org/10.3892/mco.2022.2570 |
Ejemplares similares
-
To PARPI or Not to PARPI BRCA Mutated Ovarian Cancer Following
First-line Chemotherapy, That is the Question?
por: Rose, Peter G, et al.
Publicado: (2021) -
PARPi after PARPi in epithelial ovarian cancer
por: Essel, K.G., et al.
Publicado: (2021) -
Decision Aids for Preventive Treatment Alternatives for
BRCA1/2
Mutation Carriers: a Systematic Review
por: Krassuski, Lisa Marlene, et al.
Publicado: (2021) -
Development of decision aids for female BRCA1 and BRCA2 mutation carriers in Germany to support preference-sensitive decision-making
por: Kautz-Freimuth, Sibylle, et al.
Publicado: (2021) -
Psychological factors and the uptake of preventative measures in BRCA1/2 pathogenic variant carriers: results of a prospective cohort study
por: Dick, Julia, et al.
Publicado: (2022)